Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma
- 1 January 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 111 (1) , 87-90
- https://doi.org/10.1067/mai.2003.49
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Omalizumab provides long-term control in patients with moderate-to-severe allergic asthmaEuropean Respiratory Journal, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)Pediatrics, 2001
- The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmaticsEuropean Respiratory Journal, 2001
- OmalizumabDrugs, 2001
- Anti-IgE as novel therapy for the treatment of asthmaCurrent Opinion in Pulmonary Medicine, 1999
- AsthmaPublished by American Medical Association (AMA) ,1997
- A National Estimate of the Economic Costs of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Markers of Risk of Asthma Death or Readmission in the 12 Months Following a Hospital Admission for AsthmaInternational Journal of Epidemiology, 1992
- An Economic Evaluation of Asthma in the United StatesNew England Journal of Medicine, 1992